HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 26, Nos. 09 & 10, September & October 2022 – Toxins and Medicines – Two Sides of the Same Coin       » Utilising Metal Nanoparticles as Plant Growth Regulators to Improve Crop Yield       » Remedy or Poison? How Microplastics Influence Copper Ion Toxicity in Aquatic Plants       » Synthesising Schiff Base Antimicrobial Copper Complexes With Unprecedented Speed       » Enhancing the Understanding of Past Infections With Machine Learning       » Mini, Cellular Bioweapons: Understanding the Structure and Mechanism of Stinging in Sea Anemone Nematocysts       » Converting Dead Spiders Into Gripping Tools
Vol 26, Nos. 09 & 10, September & October 2022   |   Issue PDF view/purchase
INSIDE INDUTRY
Heart Muscle Scarring Found in Patients With Hypertension Are Associated With Worse Outcomes
First-of-its-kind study by NHCS researchers shows an adverse association between heart muscle scarring (also known as myocardial fibrosis) and patients with hypertension, detected non-invasively using cardiac magnetic resonance imaging (CMR).

A recent study conducted by the National Heart Centre Singapore (NHCS) discovered that myocardial fibrosis is associated with worse cardiovascular outcomes in patients with hypertension. Myocardial fibrosis is an important prognostic marker in the development of adverse cardiovascular events, such as heart failure and death.

In Singapore, the prevalence of hypertension has shown an increase from 24.2 per cent in 2017 to 35.5 per cent in 2019 to 20201 and it is a major cause of ischemic heart disease, strokes and heart failure. Although conventional medical treatment is able to control one’s blood pressure, it does not completely ameliorate or eliminate risks of cardiovascular disease. For instance, about 30 per cent of these cardiovascular events occur in patients with well-controlled blood pressure.

In this prospective and observational study, titled REMODEL (Response of the Myocardium to Hypertrophic Conditions in the Adult Population) led by Associate Professor Calvin Chin, Clinician Scientist and Senior Consultant from the Department of Cardiology at NHCS, CMR was performed in close to 800 patients with hypertension. The patients were followed up for adverse cardiovascular events over an average period of more than three years. CMR is a useful diagnostic tool that detects heart structural abnormalities and quantifies fibrosis without the invasive sampling of heart muscle tissues.

Myocardial fibrosis typically happens in patients with previous heart attacks. Correspondingly, patients in the REMODEL study did not have previous heart attacks, hence any occurrence of myocardial fibrosis has been deduced to that of the patient’s susceptibility to blood pressure, and other reasons such as genetic predisposition and other medical co-morbidities like diabetes.

“Although anecdotal reports have previously shown the presence of heart muscle scarring in patients with hypertension, this is the first study that confirms the adverse association between scarring of heart muscle and the cardiovascular outcomes in patients with hypertension. We found that heart muscle scarring is a stronger predictor of adverse outcomes even after correcting for patients’ age, sex and systolic blood pressures,” said Assoc Prof Calvin Chin, who is also the Director of Cardiac Magnetic Resonance Imaging at NHCS.

The research team further found that the heart muscle response to hypertension in patients is heterogeneous or diverse, whereby while two patients may have similar blood pressure, their myocardial characteristics can be different. This presents opportunities to tailor and personalise treatment for hypertensive patients who have heart muscle scarring to reduce potential risk of future cardiovascular events, beyond lowering their blood pressure and achieving their blood pressure targets.

Following these findings that were published this year in the medical Journal Hypertension, Assoc Prof Calvin Chin and the team are now into the next phase of an ongoing trial REVERSE-LVH to assess the potential of reversing heart muscle scarring, through the use of specific therapies targeted at fibrosis in patients with hypertensive heart disease. REVERSE-LVH is a randomised controlled study to compare the efficacy of medications in regressing myocardial fibrosis. Patients recruited in the study would undergo CMR after a year to quantity the amount of myocardial fibrosis detected before and after treatment.

“Using CMR, a non-invasive tool to detect fibrosis has potential to improve risk-stratification of patients with hypertension. Targeted anti-fibrotic intervention, if proven effective, could have direct impact on clinical practice and help selected patients with hypertension lead better quality of life and have better health outcomes,” said Assoc Prof Calvin Chin.


Source: National Heart Centre Singapore

FORTHCOMING ISSUE  
What Has Covid Ever Done for Us?
NEWS CRUNCH  
news 2022 PDA Aseptic Processing of Biopharmaceuticals Conference
news Thailand LAB INTERNATIONAL, Bio Asia Pacific, and FutureCHEM INTERNATIONAL are ready to offer the Science and Technology Industry complete solutions this September!
news Better together: registration opens for Vitafoods Asia 2022 co-located with Fi Asia in October
news 2022 PDA Pharmaceutical Manufacturing & Quality Conference
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy